5 бет - Ең жақсы Қанның онкомаркерлерге талдауы дәрігерлері - ЖОҒ-194 дәрігерлер

Areas of Interests

• Pituitary Diseases
• Thyroid Diseases
• Obesity
• Diabetes
• Female and Male Reproductive System Diseases
• Parathyroid Diseases
• Adrenal Gland Diseases
• Osteoporosis and Metabolic Bone Diseases

Education:

• Hacettepe University Faculty of Medicine
• Bezmialem Foundation University
• Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital
• Cleveland Clinic, The Endocrinology and Metabolism Institute observer physician
• University of Piemonte Orientale, SCDU Endocrinology, Italy, observer physician
   

Experience:
 

• Mehmet Akif Inan Training and Research Hospital
• Bakirkoy Dr. Sadi Konuk Training and Research Hospital
• Bezmialem Vakif University Hospital
• Malatya State Hospital

Доктор Виола Фокс BKZ Золингендегі Гематология, Онкология және Паллиативтік медицина клиникасының бас дәрігері болып табылады. Бұл клиника сертификатталған пәнаралық қатерлі ісік орталығы. Доктор Фокс ісік ауруларын дәрі-дәрмекпен емдеуде Германия мен Еуропадағы жетекші сарапшы болып табылады. Ол осы салада 15 жылдан астам тәжірибесі бар.

Ол Германияның Онкология және Гематология-онкология Қоғамының (GDHO), Германия Дәрігерлер қауымдастығының және Американдық Қатерлі Ісік Зерттеу Қауымдастығының мүшесі болып табылады. Доктор Фокс молекулалық биология бойынша да зерттеулер жүргізеді. Оның жұмысы қатерлі ісікті емдеу мен молекулалық диагностика саласының алға жылжыуына қолдау көрсетеді.

Оның негізгі маманданған салалары химиотерапия, иммунотерапия, мақсатты терапия және радиациялық терапия болып табылады. Доктор Фокс инновациялық әдістері мен пациенттерге қамқорлық жасаудағы жоғары құлшынысымен танымал. Оның күш-жігері жоғары қалпына келу көрсеткіштерімен және әріптестерінің мойындауымен ерекшеленеді.

Professor Drach is a specialist in oncology with a PhD from the Medical University of Vienna. He has experience in research, internal medicine, hematologic oncology, nutrition, and lifestyle in cancer. He is the Director of the Josefstadt Private Clinic in Vienna and a member of the Board of Directors of the Austrian Society of Hematology and Oncology. He has published more than 120 scientific papers and given more than 200 lectures/presentations.

Dr. Victor Alexander Krol - Chief of Gastroenterology, Internal Medicine and Obesity Treatment Center at Martinus Hospital

Dr. Victor Alexander Krol is a highly qualified specialist, heading the departments of gastroenterology and internal medicine. With many years of experience and deep knowledge in his field, Dr. Krol has established himself as an outstanding expert, providing patients with comprehensive treatment and an individual approach. He actively uses the latest methods of diagnosis and treatment of diseases of the gastrointestinal tract, metabolism, as well as diseases of the cardiovascular and respiratory systems.

Dr. Krol is also the director of the certified Obesity Treatment Center at Martinus Hospital, which provides surgical and endoscopic treatments for obesity. The center uses advanced technology to diagnose and treat obesity (adiposis), including methods such as bariatric surgery, endoscopic weight loss, and specialized programs for patients with different stages of obesity. The center is certified to high standards and has excellent results in the treatment of this serious disease.

The Gastroenterology Department, headed by Dr. Krol, diagnoses and treats diseases of the stomach, intestines, liver, pancreas, and gallbladder. The doctors of the department use a wide range of methods, including endoscopic procedures, ultrasound, and other modern diagnostic technologies.

The Department of Internal Medicine covers a wide range of diseases, including cardiology, diabetology, infectology, and therapy of respiratory and renal diseases. Dr. Krol and his team provide a comprehensive approach to treatment using the most advanced methods of medicine.

Thanks to his high professionalism and humane approach to each patient, Dr. Krol deservedly enjoys the respect of colleagues and patients.

Дәрігер Северин Иборра - Штадтичес Клиникам Золингендегі Гинекология және Акушерлік Бөлімінің Бас Дәрігері. Оның міндеттеріне акушерлік, босану залы, жаңа туған нәрестелер бөлімі және гинекология кіреді. Бөлімде сонымен қатар, доктор Мануэла Зайферт басқаратын, Золингендегі Бергиш Сүт Безі Орталығындағы Сеноология/Сүт Безі Клиникасы да бар.

Дәрігер Северин Иборра Франциядан шыққан. Ол медициналық оқуын Лион Университетінде бастаған және кейін Фрайбургтегі Альберт-Людвигс Университетіне ауысып, 2007 жылы медициналық лицензиясын алған. Ол молекулярлық онкология бойынша эксперименттік зерттеулер үшін 2008 жылы докторлық дәреже алды. Тамыз 2008 ж. - қараша 2013 ж. аралығында доктор Иборра Фрайбургтегі Университет Әйелдер Клиникасында резидент ретінде жұмыс істеді. Гинекология және акушерлік бойынша мамандық емтихандарын тапсырғаннан кейін, ол сол клиникада маман ретінде мансапын жалғастырды. 2015 жылдың қарашасында ол Ахендегі РВТХ Университеті Ауруханасына аға дәрігер ретінде ауысты.

Профессор доктор Э. Стикелер жетекшілігіндегі Гинекология және Акушерлік Клиникасында, доктор Иборра 2017 жылдан 2019 жылға дейін акушерлік бөлімді басқарды. 2017 жылдың желтоқсанынан бастап ол бөлімде білім беру ұйымдастыруына жауапты болды, ал 2019 жылдың қазан айында, ол Золингенге ауыспастан бұрын, Клиниканың Басқарушы Аға Дәрігері және Кадрлық Аға Дәрігері болды.

Көптеген басылымдар мен ірі гинекологиялық конференцияларда баяндамалар жасаған ғылыми жұмысынан бөлек, доктор Иборра медициналық мамандықтарын тереңдетті. Ол Гинекологиялық Онкология Жұмыс Тобынан онкологиялық диагностика және терапия бойынша сертификаттар алды, сондай-ақ, Бұлшықет Цервикал Патологиясы және Кольпоскопия (АГЦПК), Урогинекология және Жамбас Реконструкциялық Хирургиясы (АГУП) және Гинекологтар Кәсіби Қауымдастығында (БВФ) қосымша біліктіліктер алды.

2019 жылы доктор Иборра "Гинекологиялық Онкология" және "Арнайы Акушерлік және Перинаталдық Медицина" бойынша әрі қарайғы мамандануын сәтті аяқтады. Ол өз саласында жетекші неміс медициналық қоғамдарының, соның ішінде Неміс Гинекология және Акушерлік Қоғамының, Цервикал Патология және Кольпоскопия Жұмыс Тобының, сондай-ақ Неміс Пренаталдық және Босану Медицина Қоғамының белсенді мүшесі.

Біздің Гинекология Бөлімінде Ұсынылған Емдеу Түрлері

• Гистероскопия және Кеңейту мен Кюретаж (Д&К) диагностикалық және емдік мақсаттарда.
• Жұмыртқа бездеріндегі ақаулы немесе симптомдық табысты алып тастау, қоқысын сақтау.
• Ооофорэктомия (жұмыртқа бездерін алып тастау) ауытқулар кезінде немесе көрсетілетін алдын алу ретінде.
• Миомэктомия (жатырдағы миомаларды алып тастау) жатырды сақтау.
• Миомаларды консервативті емдеу: радиология мамандары жүргізетін дәрігерлік емдеу немесе эмболизация.
• Гистерэктомия мойынды алып тастау немесе алмай.
• Түсініксіз табыстарды диагостика және тазартыу жатыр мойны, қынап және сыртқы жыныс мүшелерінде.
• Дисплазияны емдеу.
• Эндометриозды басқару.
• Қатерлі ісік емдеу сыртқы жыныс мүшелері, қынап, жатыр мойны, жатыр және жұмыртқа бездерінің қатерлі ісіктеріне арналған.
• Несеп ұстамау және/немесе жамбас органдарының пролапсы үшін емдеу.

Мүмкін болған кезде, біз барлық процедураларды лапароскопия немесе Да Винчи робот жүйесін қолданып аз инвазивті емдер ретінде ұсынамыз.

Under his leadership, the hospital is actively expanding its services, including paediatric cardiology and intensive care, and is planning to establish an interdisciplinary center for parents and children on the basis of the Department of Paediatrics.

Dr. Propson's many years of experience have established him as a leading expert in neonatology and paediatric cardiology in Germany and Europe. His dedication and commitment to the highest level of care for young patients is reflected in his work. Dr. Propson's research and scientific publications demonstrate his in-depth knowledge and commitment to development in paediatrics.

For many years Dr. Propson worked as a leading physician in the Department of Paediatrics and Adolescent Medicine at the Leverkusen Clinic in Leverkusen, Germany, where he was also responsible for managing the paediatric intensive care unit. In addition to his primary work, Dr. Propson devotes a great deal of time to continuing education to ensure that his patients receive the most up-to-date treatments in his department.

His unique professional qualities and qualifications set him apart from other physicians. Dr. Propson's patients can rest assured that they are in good hands at the Department of Paediatrics and Adolescent Medicine at the Academic Hospital Solingen.

Membership in societies:

German Association of Physicians

Expert of scientific journals

Specialisations:

Emergency medicine

Intensive care

Paediatric cardiology

Neonatology

Work Experience:

2006: Graduation from the Faculty of Medicine

2006 - 2011: Specialization as a specialist in paediatrics and adolescent medicine.

2011 - 2023: Lead physician in the Department of Paediatrics and Adolescent Medicine at the Leverkusen Clinic.

2023: Chief physician in the Department of Paediatrics at the Academic Hospital Solingen.

Membership in societies:

Expert of scientific journals 

Close co-operation with leading surgeons

Membership of the German Medical Association 

Specialities:

Introduction of new and modern techniques in the field of oncological surgery
General and visceral surgery

Minimally invasive surgery

Gastrointestinal oncology surgery

Oncological surgery

Haemorrhoids treatment

Additional clinical specialisation in minimally invasive and hernia surgery

Surgery and transplantation of the pancreas

Work Experience:

2005: Specialist in the field of surgery

2008: Appointed Senior Consultant specialising in pancreatic surgery and transplantation

2010: Coordinator of the Pancreatic Cancer Centre (Oncocert)

2013: Specialist in visceral surgery

2014: Managing Senior Physician, additional clinical specialisation in minimally invasive and hernia surgery

2019: Chief Surgeon of the Colorectal Cancer Centre Bochum (the first certified colorectal cancer centre in Germany and one of the first certified leading colorectal centres in Europe)

2021: Chief Surgeon of the Department of Surgery at the Academic Hospital Solingen

Thanks to the professor and his team, the department has been modernised by introducing modern surgical methods of treatment and especially improved methods of post-operative recovery. The Department of Surgery at the Solingen Clinic is now further expanding its focus on minimally invasive surgery in the direction of robotics. The clinic has allocated a huge budget for the purchase of state-of-the-art equipment in order to offer patients a full range of surgical methods for the treatment of benign and malignant diseases of the oesophagus, lungs, stomach, liver, pancreas and intestines according to current guidelines and using the most modern technical equipment.

Professor Schenker is an active researcher and lecturer. He lectures at medical universities and organises seminars and workshops for colleagues. He cooperates closely with the Cancer Centre, the Pancreatic Cancer Treatment Centre, the Intestinal Cancer Treatment Centre and the Interregional Trauma Centre.

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

EDUCATION:

• Turhan and Mediha Tansel Primary School (1979–1984)
• Kültür College (1984–1988)
• Semiha Şakir High School (1988–1991)
• Marmara University Faculty of Medicine (1991–1997)
• Marmara University Faculty of Medicine, Neurosurgery Department, Specialist Training (1997–2002)
• Title of Associate Professor in Neurosurgery (May 31, 2021)

ADDITIONAL TRAINING:

• "Visiting Physician," University of Southern California, Department of Neurosurgery (1998)
• "Microsurgery Training," GATA (Gülhane Military Medical Academy), Ankara Education and Research Hospital (2003)

PROFESSIONAL EXPERIENCE:

• Gülhane Military Medical Academy Haydarpaşa Training and Research Hospital (2002–2003)
• Dr. Lütfi Kırdar Kartal Training and Research Hospital (2003–2005)
• Private Avicenna Ataşehir Hospital (2005–2012)
• Private 29 Mayıs Hospital (2012–2013)
• Maltepe State Hospital (2013–2018)
• Kartal Dr. Lütfi Kırdar City Hospital (2018–2020)
• Private Academic Hospital (2020–2022)
• Hisar Intercontinental Hospital (2022–2024)
• Private Medipol Acıbadem Regional Hospital (2024–Present)

ADMINISTRATIVE AND ACADEMIC ROLES:

• Board Member, Neurosurgical Society (2006–2009)
• Head of the Emergency Department, Maltepe State Hospital (2014–2016)
• Deputy Chief Physician, Private Academic Hospital (2020–2021)
• Advisory Board Member, Beykent University Faculty of Medicine (2018–2024)
• Faculty Member, Galata University Faculty of Health Sciences (2022–2024)
• Director, Continuous Education Center, Galata University (2022–2024)

Dr. Joseba Rebollo Liceaga is a seasoned medical oncologist with a comprehensive background in oncology.​

Education and Training:

Graduated in Medicine and Surgery from the University of Navarra (1985).​

Completed residency in Oncology in 1987.​

Specialist in Medical Oncology at the Clínica Universidad de Navarra (1991).​

Professional Experience:

Head of the Oncology Department at Clínica San Miguel de Navarra (1991–2004).​

Associate Physician at the University Clinic of the Faculty of Medicine, University of Navarra (1995–2002).​

Adjunct Physician at the Oncology Platform, Hospital Quirónsalud Torrevieja (2004–2014).

Head of the Oncology Department at Hospital General de Villalba (2014–2019).​

Currently practices as a Medical Oncology Specialist at Quirónsalud Alicante.​

Certifications and Training:

Completed multiple accredited courses in Multidisciplinary Oncology between 2003 and 2006.​

Research and Publications:

Authored research on electrochemotherapy and multidisciplinary treatment approaches in oncology.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Erkancakir is a specialist in pediatric chest diseases. He has experience with acute and chronic respiratory problems, respiratory tract infections, and bronchoscopic procedures. His areas of focus include asthma, sleep-related breathing disorders, cystic fibrosis, and tuberculosis.

He completed his medical degree at Istanbul University. He continued his specialty training at Göztepe Training and Research Hospital and Marmara University. Dr. Erkancakir has worked at leading institutions, such as Bezmialem Vakıf University and Süreyyapaşa Chest Diseases Training and Research Hospital.

He is an active member of several professional organizations, including the Turkish Thoracic Society and the European Respiratory Society. Dr. Erkancakir has received more than 20 national and international awards for his research and presentations, especially in pediatric pulmonology and cystic fibrosis.

Dr. Binnur Simsek is a gastroenterology specialist. She has experience in liver cirrhosis, portal hypertension, hepatocellular carcinoma, liver transplantation, and viral hepatitis (B, C, Delta). She also treats alcoholic and non-alcoholic fatty liver disease, peptic ulcers, gastrointestinal bleeding, and inflammatory bowel diseases such as ulcerative colitis and Crohn’s colitis.

She completed her medical and gastroenterology training at Istanbul University Faculty of Medicine. Dr. Simsek has worked at Istanbul University, Sanlıurfa Education and Research Hospital, Liv Hospital, and Istinye University. She is a member of the Turkish Association for the Study of the Liver and the Turkish Society of Gastroenterology.

Dr. Itir Sirinoglu Temiz is a Professor of Hematology. She specializes in lymphoma, acute and chronic leukemias, multiple myeloma, thrombocytopenias, thrombosis, anemia, and bone marrow failure. She graduated with honors from Istanbul University Cerrahpaşa Faculty of Medicine. She completed her hematology training at Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital.

Dr. Sirinoglu Temiz has held key academic and administrative positions. She served as Head of Internal Medicine at IAU Faculty of Medicine. She was also Education and Administrative Manager at SBÜ Bakırköy Dr. Sadi Konuk EAH Hematology Clinic. She has broad experience in adult hematology, stem cell transplantation, and therapeutic apheresis. She currently practices at Liv Hospital.

Areas of Interests

• MR Linac
• Three Dimensional Brachytherapy
• Four Dimensional (4D) Radiotherapy
• Stereotactic RT & IMRT
• Breast Cancer, Gynecological Cancers
• Head – Neck Cancers
• Urological Tumors, Gastrointestinal Cancers
• Lung Cancer
• Central Nervous System Tumors & Metastases
• Skin Cancers
• Soft Tissue Tumors

Education:

• Istinye University Medical Faculty, Professor Doctor (2017 – Continued)
• Istine University Medical Faculty Associate Professor Doctor (2016 – 2017)
• Liv Hospital Radiation Medicine Center, Tbilisi, Georgia, Radiation Oncology Consulting Docor (2016 – 2019)
• Liv Hospital, Radiation Oncology (2015 – Continued)
• Istanbul University Oncology Institution, Associate Professor (2012 – 2015)
• Stereotactic Radiotherapy, Thoracic Oncology, University of North Carolina, NC, USA (2010 – 2011)
• Kocaeli University Radiation Oncology Department, Associate Professor Assistant (2006 – 2009)
• GATA Radiation Oncology Department, Specialist Doctor, Reserve Officer (2004 – 2005)
• Istanbul University, Medical Faculty, Dr.R.A. (1999 – 2004)
• Istanbul University, Medical Faculty, Under-Graduate (1993 – 1999)
   

Experience:

• Istinye University Medical Faculty
• Liv Hospital Ulus
• Istanbul University Oncology Institution
• University of North Carolina, NC, USA
• Kocaeli University Medical Faculty
• Istanbul University, Medical Faculty

Dr. Omer Burcak Binicier is a gastroenterology specialist with strong medical training. He earned his medical degree at Ege University. He completed his internal medicine and gastroenterology specialization at Dokuz Eylül University Faculty of Medicine. Dr. Binicier has over ten years of clinical experience. He has held key positions at SBÜ Tepecik Training and Research Hospital and İzmir Bayraklı City Hospital. He also gained international experience at Korea University.

Dr. Binicier diagnoses and treats a wide range of gastrointestinal diseases. His expertise includes early colon and stomach cancers, inflammatory bowel diseases, liver and pancreatic disorders, and digestive system cancers. He uses advanced endoscopic techniques such as EMR, ESD, ERCP, and endoscopic ultrasound. He is also skilled in minimally invasive obesity treatments. His clinical skills are built on years of hands-on work in top medical centers.